NASDAQ: GTHXG1 Therapeutics Inc Stock Ownership - Who owns G1 Therapeutics?
Insider buying vs selling
Have G1 Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Mark A. Velleca | Director | 2023-08-08 | 57,286 | $0.39 | $22.34kBuy |
| Mark A. Velleca | Director | 2023-08-08 | 2,714 | $0.30 | $814.20Buy |
| Mark A. Velleca | Director | 2023-08-08 | 2,714 | $2.02 | $5.48kSell |
| Mark A. Velleca | Director | 2023-08-08 | 57,286 | $2.00 | $114.51kSell |
| John E. Jack Bailey Jr. | President and CEO | 2023-07-05 | 2,719 | $2.45 | $6.67kSell |
| Andrew Perry | Chief Commercial Officer | 2023-07-05 | 355 | $2.45 | $871.17Sell |
| Terry L. Murdock | Chief Operating Officer | 2023-07-05 | 1,361 | $2.45 | $3.34kSell |
| Rajesh Malik | Chief Medical Officer | 2023-07-05 | 1,361 | $2.45 | $3.34kSell |
| Jennifer K. Moses | CFO | 2023-01-05 | 729 | $5.41 | $3.94kSell |
| James S. Hanson | General Counsel | 2023-01-05 | 729 | $5.41 | $3.94kSell |
GTHX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GTHX insiders and whales buy or sell their stock.
GTHX Shareholders
What type of owners hold G1 Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Clay Thorp | 14.30% | 7,411,440 | $17.94M | Insider |
| Ra Capital Management LP | 9.58% | 4,968,488 | $12.02M | Insider |
| Fredric N. Eshelman | 7.12% | 3,689,151 | $8.93M | Insider |
| Eshelman Ventures LLC | 6.63% | 3,439,151 | $8.32M | Insider |
| Medimmune Ventures Inc | 5.69% | 2,950,630 | $7.14M | Insider |
| Vanguard Group Inc | 3.76% | 1,950,068 | $4.72M | Institution |
| Blackrock Inc | 2.16% | 1,120,307 | $2.71M | Institution |
| Millennium Management LLC | 2.02% | 1,048,995 | $2.54M | Institution |
| Raymond James Associates | 1.79% | 925,776 | $2.24M | Institution |
| Jacobs Levy Equity Management Inc | 1.11% | 573,256 | $1.39M | Institution |
GTHX vs Biotech Stocks
G1 Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.